Clinical evaluation of basic fetoprotein in testicular cancer.

[1]  H. D. de Bruijn,et al.  Significance of human chorionic gonadotropin, alpha‐fetoprotein, and pregnancy‐specific beta‐1‐glycoprotein in the detection of tumor relapse and partial remission in 126 patients with nonseminomatous testicular germ cell tumors , 1985, Cancer.

[2]  S. Morinaga,et al.  Human chorionic gonadotropin and alpha‐fetoprotein in testicular germ cell tumors. An immunohistochemical study in comparison with tissue concentrations , 1983, Cancer.

[3]  N. Javadpour.  Multiple biochemical tumor markers in seminoma. A double‐blind study , 1983, Cancer.

[4]  P. Lange,et al.  Marker half-life analysis as a prognostic tool in testicular cancer. , 1982, The Journal of urology.

[5]  N. Javadpour,et al.  Lactic dehydrogenase in the monitoring and prognosis of testicular cancer , 1981, Cancer.

[6]  S. Hsu,et al.  The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. , 1981, American journal of clinical pathology.

[7]  P. Scardino,et al.  Relevance of biochemical tumor markers and lymphadenectomy in management of non-seminomatous testis tumors: current perspective. , 1980, Transactions of the American Association of Genito-Urinary Surgeons.

[8]  N. Javadpour.  Applications of biologic tumor markers in testicular cancer. , 1979, Cancer treatment reports.

[9]  T. Waldmann,et al.  Human chorionic gonadotropin (HCG) and alpha‐fetoprotein (AFP) in sera and tumor cells of patients with testicular seminoma. A prospective study , 1978, Cancer.

[10]  M. Ishii.  A New Carcinoembryonic Protein Characterized by Basic Property , 1978 .

[11]  H. D. Cox,et al.  The value of serum tumor markers in the staging and prognosis of germ cell tumors of the testis. , 1977, The Journal of urology.